ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos195.71 M177.8 M191.55 M177.59 M196.14 M743.07 MInvestigación y desarrollo——————Beneficio operativo-167.69 M74.67 M100.13 M133.8 M-283.44 M25.16 MTotal de ingresos no operativos-25.85 M-10.81 M1.25 M-21.2 M8.73 M-22.02 MGastos por intereses, netos de intereses capitalizados28.23 M27.88 M29.97 M25.4 M23.77 M107.03 MIngresos no operativos, una vez deducidos los gastos por intereses-31.38 M-26.48 M-28.87 M-23.98 M-27.15 M-106.48 MIngresos/gastos extraordinarios-22.7 M-12.21 M154 K-22.62 M12.1 M-22.58 MBeneficio antes de impuestos93.11 M35.98 M71.42 M87.2 M-99.5 M95.09 MParticipación en los beneficios——————Impuestos-3.04 M10.1 M18.73 M31.64 M-17.81 M42.66 MParticipación minoritaria748 K409 K367 K1.13 M265 K2.17 MOtros ingresos/gastos después de impuestos-24.35 M-3.73 M1.47 M-1.04 M802 K-2.5 MBeneficio neto antes de actividades interrumpidas-214.5 M25.47 M52.33 M54.42 M-276.56 M-144.34 MOperaciones suspendidas——————Beneficio neto-214.5 M25.47 M52.33 M54.42 M-276.56 M-144.34 MAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas-215.7 M25.47 M52.33 M54.42 M-276.56 M-144.34 MBeneficio básico por acción-4.20.51.061.11-5.58-2.91Beneficio por acción diluido-4.170.51.061.1-5.57-2.91Número medio de acciones ordinarias51.38 M50.68 M49.15 M49.21 M49.56 M198.6 MAcciones diluidas51.63 M50.85 M49.32 M49.43 M49.56 M199.16 MEBITDA395.15 M833.25 M849.49 M872.86 M8.47 M2.56 BEBIT293.05 M712.89 M729.99 M787.7 M-69.81 M2.16 BCosto de los ingresos27 M6.76 M4.3 M-370 K1.75 M12.44 MOtros costes de producción27 M6.76 M4.3 M-370 K1.75 M12.44 MAmortización y depreciación (flujo de caja)102.1 M120.36 M119.51 M85.16 M78.28 M403.31 M
Charles River Laboratories International Inc
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.